🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Multiple Sclerosis
Clinical trial register · United Kingdom · industry-sponsored

Multiple Sclerosis Trials in the UK

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2852 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
2852
Studies in scope
industry-sponsored, all four open statuses
1378
Recruiting now
open to new participants
540
Lead sponsors
across recruiting studies
Top sites
London 10 Salford 5 Exeter 3 Newcastle upon Tyne 3 Nottingham 3
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Hoffmann-La Roche4 Sanofi2 Novartis Pharmaceuticals2 Juno Therapeutics, Inc., a Bristol-Myers Squibb Company1 AstraZeneca1
Site city
London10 Salford5 Exeter3 Newcastle upon Tyne3 Nottingham3
All 21 cities
Target enrolment
to
14 of 2852 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
NCT07224373Multiple Sclerosis
AstraZeneca
Phase 1
24
Cambridge, London
2025-12-09
Recruiting
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
NCT06735248Multiple Sclerosis
ModernaTX, Inc.
Phase 2
180
Bristol, Cardiff, Edinburgh, Glasgow, London, Newcastle upon Tyne, Sheffield
2025-04-16
Active, closed
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis
NCT07667322Multiple Sclerosis
Hoffmann-La Roche
Phase 1
75
Nottingham, Swansea
2024-12-17
Active, closed
Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis
NCT06444113Multiple Sclerosis
Novartis Pharmaceuticals
Phase 4
24
Cambridge, London, Oxford, Salford
2024-11-25
Active, closed
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
NCT06220201Multiple Sclerosis, Myasthenia Gravis
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
120
Manchester, London, Salford
2024-03-28
Active, closed
A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis
NCT06220669Multiple Sclerosis
Eli Lilly and Company
Phase 2
63
Nottingham
2024-03-19
Active, closed
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
NCT06141486Multiple Sclerosis
Sanofi
Phase 3
943
Gwent, Cardiff, Exeter, London, Newcastle upon Tyne, Inverness, Canterbury, Salford
2023-12-27
Active, closed
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473Multiple Sclerosis
Sanofi
Phase 3
1,655
Exeter, London, Inverness, Canterbury, Salford
2023-12-13
Recruiting
Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
NCT05658497Multiple Sclerosis
Biogen
Observational
908
Salford
2023-10-27
Active, closed
A Novel Wearable Digital Biomarker for Detecting Changes in Multiple Sclerosis (MS) Condition
NCT05781113Multiple Sclerosis
Celestra Health Systems
Observational
90
London
2023-07-01
Active, closed
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
NCT05269004Multiple Sclerosis
Hoffmann-La Roche
Phase 3
1,300
Nottingham, Exeter, Liverpool, London, Newcastle, Swansea
2022-05-03
Active, closed
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
NCT04548999Multiple Sclerosis
Hoffmann-La Roche
Phase 3
769
London, Newcastle upon Tyne, Plymouth
2020-12-03
Active, closed
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
NCT04544436Multiple Sclerosis
Hoffmann-La Roche
Phase 3
864
Plymouth
2020-11-26
Active, closed
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
NCT01892722Multiple Sclerosis
Novartis Pharmaceuticals
Phase 3
240
West Midlands, Edinburgh, London
2013-07-26
Rows per page Showing 1–14 of 14
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 18 September 2026. https://priyalifescience.com/clinical-trials-uk/condition/multiple-sclerosis

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.